Product
Capivasertib
Aliases
AZD5363, Truqap
Name
TRUQAP
INN Name
capivasertib
FDA Approved
Yes
16 clinical trials
1 organization
61 indications
1 document
Indication
Non-Hodgkin LymphomaIndication
Breast NeoplasmsIndication
Solid TumourIndication
Breast CancerIndication
Breast Cancer, Stage IVIndication
Triple-Negative Breast CarcinomaIndication
LymphomaIndication
Malignant NeoplasmIndication
Hematopoietic and Lymphoid Cell NeoplasmIndication
Malignant Solid NeoplasmIndication
Multiple MyelomaIndication
Hormone-Sensitive Prostate CancerIndication
Prostate CancerIndication
Bladder CancerIndication
Cervical CancerIndication
Colon CancerIndication
Colorectal cancerIndication
Endometrial CancerIndication
Esophageal cancerIndication
GliomaIndication
Head and Neck CarcinomaIndication
Renal Cell CarcinomaIndication
Liver CancerIndication
Lung CancerIndication
lymphomaIndication
Uterine CancerIndication
MelanomaIndication
Ovarian CancerIndication
Pancreatic CarcinomaIndication
Rectal cancerIndication
Bladder CarcinomaIndication
Recurrent Cervical CarcinomaIndication
Recurrent Colorectal CancerIndication
Colorectal CancerIndication
Esophageal carcinomaIndication
Recurrent Gastric CarcinomaIndication
Recurrent GliomaIndication
Recurrent Head and Neck CarcinomaIndication
Recurrent Lung CarcinomaIndication
Recurrent Malignant Solid NeoplasmIndication
MeningiomaIndication
Neurofibromatosis Type 2 Gene MutationIndication
Endometrial Mixed Cell AdenocarcinomaIndication
Endometrial Serous AdenocarcinomaIndication
Endometrial CarcinomaIndication
Endometrioid AdenocarcinomaIndication
Stage IV Uterine Corpus Cancer AJCC v8Indication
BRCA1 Mutation CarrierIndication
BRCA2 mutation carrierIndication
Estrogen Receptor NegativeIndication
HER2/Neu NegativeIndication
Ovarian Serous AdenocarcinomaIndication
Progesterone Receptor NegativeIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Recurrent Uterine Corpus CarcinomaIndication
Stage III Uterine Corpus Cancer AJCC v7Indication
Breast cancerIndication
Stage IV Uterine Corpus Cancer AJCC v7Indication
Gastric CancerClinical trial
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel vs Placebo+Paclitaxel as First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC.Status: Active (not recruiting), Estimated PCD: 2024-03-18
Clinical trial
A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)Status: Active (not recruiting), Estimated PCD: 2023-08-22
Clinical trial
An Open-label, Fixed-sequence Study to Assess the Effect of Repeated Doses of Capivasertib on the Pharmacokinetics of Oral Midazolam (a CYP450 3A Probe) in Patients With Advanced Solid TumoursStatus: Completed, Estimated PCD: 2023-02-06
Clinical trial
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)Status: Active (not recruiting), Estimated PCD: 2023-08-16
Clinical trial
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase InhibitorStatus: Active (not recruiting), Estimated PCD: 2022-08-15
Clinical trial
A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-11-14
Clinical trial
A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Phase II Study for Premenopausal Metastatic or Locally Advanced Breast Cancer Patients: Capivasertib, Goserelin, Fulvestrant With/Without Durvalumab, Versus Goserelin, Fulvestrant, and Durvalumab, Versus Goserelin/ Fulvestrant.Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumetinib or Capivasertib, or Ceralasertib Monotherapy in Patients With Metastatic Triple-Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
MATCH Treatment Subprotocol Y: AZD5363 in Patients With Tumors With AKT MutationsStatus: Active (not recruiting), Estimated PCD: 2019-11-08
Clinical trial
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.Status: Active (not recruiting), Estimated PCD: 2024-10-04
Clinical trial
Precision Neoadjuvant Therapy for High Risk Localized Prostate Cancer With PTEN LossStatus: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
Molecular Analysis for Therapy Choice (MATCH)Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway MutationsStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube CancerStatus: Active (not recruiting), Estimated PCD: 2025-12-30
Document
DailyMed Label: TRUQAPOrganization
AstraZeneca Pharmaceuticals LP